Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy
Description:
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.
Sponsor:
Jonsson Comprehensive Cancer Center (UCLA)
Contacts:
Rejah Marie Nabong (Clinical Trials Program Manager)rmalano@mednet.ucla.edu
310-206-7372
Government Study Link:
NCT05398302 - Click here to see study onClinicalTrials.gov
177Lu-PSMA
- PSMA
- Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy
- Histologically confirmed prostate cancer
- Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial
- Patients with significant congenital or acquired bleeding disorders
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
Los Angeles, California, United States
Principal Investigator
Johannes Czernin, MD
